A retrospective trial evaluating efficacy and safety of Brentuximab-vedotin as salvage therapy in R/R HL patients in Taiwan
Latest Information Update: 09 Mar 2020
Price :
$35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 09 Mar 2020 New trial record